Effect of Curcumin on chronic gastritis related to helicobacter pylori

Evalution of Curcumin on level of oxidative stress factors and gastric histoplathology in patients with chronic gastrits related to helicobacter pylori

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016012826238N1

Enrollment

100

Registered

2016-03-10

Start date

2016-02-09

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Gastritis. Chronic gastritis, unspecified

Interventions

Intervention 1: Control group: triple therapy bismuth subcitrate 120 mg / kg four times a day, tetracycline 500 mg / kg four times a day and metronidazole 400 mg / kg three times daily. Intervention

Treatment - Drugs

Control group: triple therapy bismuth subcitrate 120 mg / kg four times a day, tetracycline 500 mg / kg four times a day and metronidazole 400 mg / kg three times daily.

triple therpy +Curcumin with 30 mg/twice in day for 8 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18 to 65 years? confirm of chronic gastritis according to histopathologic assay? presence of abdominal symptoms related to chronic gastritis. Exclusion criteria: recent use of antibiotics in the last 6 months? pregnancy? lactation? recent surgical procedures? alcohol? systemic diseases like coronary artery disease? diabetes? collagen vascular and central nervous system? age <18 years and above 70 years.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Malondialdehyde. Timepoint: Initial and after 8 weeks. Method of measurement: Randox Kit.;Total Antioxidant Capacity. Timepoint: Initial and after 8 weeks. Method of measurement: Randox Kit.;Glutathione peroxidase. Timepoint: Initial and after 8 weeks. Method of measurement: Randox Kit.;Prostaglandin E2. Timepoint: Initial and after 8 weeks. Method of measurement: RAI.;Chronic Gastritis. Timepoint: Initial and after 8 weeks. Method of measurement: Histology.;Endoscopic Inflammation Score. Timepoint: Initial and after 8 weeks. Method of measurement: Endoscopy.;DNA Oxidative Damage. Timepoint: Initial and after 8 weeks. Method of measurement: DNA Oxidative Damage Kit.	—

Measure

Time frame

Malondialdehyde. Timepoint: Initial and after 8 weeks. Method of measurement: Randox Kit.;Total Antioxidant Capacity. Timepoint: Initial and after 8 weeks. Method of measurement: Randox Kit.;Glutathione peroxidase. Timepoint: Initial and after 8 weeks. Method of measurement: Randox Kit.;Prostaglandin E2. Timepoint: Initial and after 8 weeks. Method of measurement: RAI.;Chronic Gastritis. Timepoint: Initial and after 8 weeks. Method of measurement: Histology.;Endoscopic Inflammation Score. Timepoint: Initial and after 8 weeks. Method of measurement: Endoscopy.;DNA Oxidative Damage. Timepoint: Initial and after 8 weeks. Method of measurement: DNA Oxidative Damage Kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Reza Hafezi Ahmadi

Ilam University of Medical Science

reza.ahmadi.54@gmail.com+98 84 3224 3320

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026